AstraZeneca plc vs KeyCorp — how do they compare? AstraZeneca plc trades at $158.42 (market cap $248.14B), while KeyCorp trades at $22.7 (market cap $24.32B). The key difference: AstraZeneca plc is far larger — about 10.2× KeyCorp's market cap, and KeyCorp pays the higher dividend (3.61%). Which is the better fit depends on your goals.
| AZN | KEY | |
|---|---|---|
Market Cap | $248.14B | $24.32B |
Sector | Health | Financials |
52-Week High | $209.48 | $23.99 |
52-Week Low | $147.06 | $16.78 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | 3.61% |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →